Tetrahydroberberrubine improves hyperlipidemia by activating the AMPK/SREBP2/PCSK9/LDL receptor signaling pathway.
Feng J, Xu R, Dou Z, Hao Y, Xu R, Khoso MA, Shi Y, Liu L, Sun H, Chen C, Li X, Liu H, Han W, Cheng M, Tang P, Li J, Zhang Y, Liu X.
Feng J, et al. Among authors: dou z.
Eur J Pharmacol. 2025 Feb 15;989:177228. doi: 10.1016/j.ejphar.2024.177228. Epub 2025 Jan 2.
Eur J Pharmacol. 2025.
PMID: 39755242